Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Sepsis: Personalized Medicine Utilizing 'Omic' Technologies-A Paradigm Shift?

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{8dec83dea94d4519a67f79720997c746,
title = "Sepsis: Personalized Medicine Utilizing 'Omic' Technologies-A Paradigm Shift?",
abstract = "Sepsis has over the years proven a considerable challenge to physicians and researchers. Numerous pharmacological and non-pharmacological interventions have been tested in trials, but have unfortunately failed to improve the general prognosis. This has led to the speculation that the sepsis population may be too heterogeneous to be targeted with the traditional one treatment suits all' approach. Recent advances in genetic and biochemical analyses now allow genotyping and biochemical characterisation of large groups of patients via the 'omics' technologies. These new opportunities could lead to a paradigm shift in the approach to sepsis towards personalised treatments with interventions targeted towards specific pathophysiological mechanisms activated in the patient. In this article, we review the potentials and pitfalls of using new advanced technologies to deepen our understanding of the clinical syndrome of sepsis.",
author = "Itenov, {Theis Skovsgaard} and Murray, {Daniel D} and Jensen, {Jens Ulrik St{\ae}hr}",
year = "2018",
month = "9",
day = "7",
doi = "10.3390/healthcare6030111",
language = "English",
volume = "6",
pages = "E111",
journal = "Healthcare (Basel, Switzerland)",
issn = "2227-9032",
number = "3",

}

RIS

TY - JOUR

T1 - Sepsis

T2 - Personalized Medicine Utilizing 'Omic' Technologies-A Paradigm Shift?

AU - Itenov, Theis Skovsgaard

AU - Murray, Daniel D

AU - Jensen, Jens Ulrik Stæhr

PY - 2018/9/7

Y1 - 2018/9/7

N2 - Sepsis has over the years proven a considerable challenge to physicians and researchers. Numerous pharmacological and non-pharmacological interventions have been tested in trials, but have unfortunately failed to improve the general prognosis. This has led to the speculation that the sepsis population may be too heterogeneous to be targeted with the traditional one treatment suits all' approach. Recent advances in genetic and biochemical analyses now allow genotyping and biochemical characterisation of large groups of patients via the 'omics' technologies. These new opportunities could lead to a paradigm shift in the approach to sepsis towards personalised treatments with interventions targeted towards specific pathophysiological mechanisms activated in the patient. In this article, we review the potentials and pitfalls of using new advanced technologies to deepen our understanding of the clinical syndrome of sepsis.

AB - Sepsis has over the years proven a considerable challenge to physicians and researchers. Numerous pharmacological and non-pharmacological interventions have been tested in trials, but have unfortunately failed to improve the general prognosis. This has led to the speculation that the sepsis population may be too heterogeneous to be targeted with the traditional one treatment suits all' approach. Recent advances in genetic and biochemical analyses now allow genotyping and biochemical characterisation of large groups of patients via the 'omics' technologies. These new opportunities could lead to a paradigm shift in the approach to sepsis towards personalised treatments with interventions targeted towards specific pathophysiological mechanisms activated in the patient. In this article, we review the potentials and pitfalls of using new advanced technologies to deepen our understanding of the clinical syndrome of sepsis.

U2 - 10.3390/healthcare6030111

DO - 10.3390/healthcare6030111

M3 - Review

VL - 6

SP - E111

JO - Healthcare (Basel, Switzerland)

JF - Healthcare (Basel, Switzerland)

SN - 2227-9032

IS - 3

ER -

ID: 56537369